← Back to Screener
Dare Bioscience, Inc. Common Stock (DARE)
Price$2.87
Favorite Metrics
Price vs S&P 500 (26W)28.49%
Price vs S&P 500 (4W)101.35%
Market Capitalization$41.79M
All Metrics
P/CF (Annual)4.70x
Book Value / Share (Quarterly)$0.20
P/TBV (Annual)3.04x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-53.12%
Cash Flow / Share (Quarterly)$-0.71
Price vs S&P 500 (YTD)44.77%
Gross Margin (TTM)71.87%
Net Profit Margin (TTM)-892.44%
EPS (TTM)$-0.88
10-Day Avg Trading Volume1.46M
EPS Excl Extra (TTM)$-0.88
Revenue Growth (5Y)66.71%
EPS (Annual)$-1.20
ROI (Annual)-137.64%
Gross Margin (Annual)71.29%
Net Profit Margin (5Y Avg)-14661.44%
Cash / Share (Quarterly)$1.70
Revenue Growth QoQ (YoY)-94.58%
ROA (Last FY)-41.26%
Revenue Growth TTM (YoY)1331.80%
EBITD / Share (TTM)$-0.70
ROE (5Y Avg)-867.89%
Operating Margin (TTM)-924.94%
Cash Flow / Share (Annual)$-0.71
P/B Ratio14.70x
P/B Ratio (Quarterly)9.70x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)22.80x
Net Interest Coverage (TTM)-92.72x
ROA (TTM)-34.39%
EPS Incl Extra (Annual)$-1.20
Current Ratio (Annual)1.14x
Quick Ratio (Quarterly)1.08x
3-Month Avg Trading Volume0.29M
52-Week Price Return-1.03%
EV / Free Cash Flow (Annual)1.98x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$-0.02
P/S Ratio (Annual)40.56x
Asset Turnover (Annual)0.03x
52-Week High$9.19
Operating Margin (5Y Avg)-12521.20%
EPS Excl Extra (Annual)$-1.20
CapEx CAGR (5Y)80.70%
Tangible BV CAGR (5Y)6.51%
26-Week Price Return35.38%
Quick Ratio (Annual)1.08x
13-Week Price Return47.18%
Total Debt / Equity (Annual)2.42x
Current Ratio (Quarterly)1.14x
Enterprise Value$23.967
Revenue / Share Growth (5Y)10.80%
Asset Turnover (TTM)0.04x
Book Value / Share Growth (5Y)-38.32%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1300.66%
Cash / Share (Annual)$1.70
3-Month Return Std Dev118.92%
Net Income / Employee (TTM)$-0
ROE (Last FY)-471.37%
Net Interest Coverage (Annual)-229.44x
EPS Basic Excl Extra (Annual)$-1.20
P/FCF (TTM)33.76x
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)2.42x
EPS Incl Extra (TTM)$-0.88
Receivables Turnover (Annual)0.00x
ROI (TTM)-50.40%
P/S Ratio (TTM)39.74x
Pretax Margin (5Y Avg)-14661.44%
Revenue / Share (Annual)$0.09
Tangible BV / Share (Annual)$0.13
Price vs S&P 500 (52W)-35.67%
Year-to-Date Return48.70%
5-Day Price Return64.00%
EPS Normalized (Annual)$-1.20
ROA (5Y Avg)-68.25%
Net Profit Margin (Annual)-1300.66%
Month-to-Date Return57.69%
Cash Flow / Share (TTM)$-0.48
EBITD / Share (Annual)$-1.04
Operating Margin (Annual)-1315.52%
LT Debt / Equity (Annual)1.90x
ROI (5Y Avg)-801.15%
LT Debt / Equity (Quarterly)1.90x
EPS Basic Excl Extra (TTM)$-0.88
P/B Ratio (Annual)9.70x
Pretax Margin (TTM)-892.44%
Book Value / Share (Annual)$0.20
Price vs S&P 500 (13W)44.80%
Beta1.29x
P/FCF (Annual)8.67x
Revenue / Share (TTM)$0.07
ROE (TTM)-175.58%
52-Week Low$1.27
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.10
4.10
4.10
4.10
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
DAREDare Bioscience, Inc. Common Stock | 39.74x | 1331.80% | 71.87% | — | $2.87 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Dare Bioscience is a biopharmaceutical company developing therapies in women's health, focused on contraception, fertility, and sexual health. The company's first approved product, XACIATO, is a prescription vaginal gel for treating bacterial vaginosis in females ages 12 and older. Its pipeline includes two clinical-stage candidates: Ovaprene and Sildenafil Cream.